Title : Preservation of Skeletal Muscle Mass During GLP 1 Receptor Agonist Mediated Weight Loss Clinical Determinants Risk Stratification and Evidence Based Mitigation Strategies
Abstract:
Background and rationale. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide and tirzepatide, consistently achieve 10–22% total body weight reduction in clinical trial populations; however, cross-sectional and longitudinal data increasingly demonstrate that 25–40% of this weight loss may be attributable to lean mass depletion, with appendicular skeletal muscle mass (ASMM) loss disproportionately exceeding that predicted by isoenergetic caloric restriction alone. This phenomenon poses a clinically significant paradox: while GLP-1RA therapy reduces adiposity-related comorbidity burden, concurrent sarcopaenic remodelling may accelerate functional decline — particularly in older adults, individuals with pre-existing low muscle reserve, and patients with type 2 diabetes mellitus in whom myosteatosis is prevalent. Despite this recognised risk, no evidence-based clinical protocol currently exists to standardise muscle mass monitoring or prescribe targeted mitigation during GLP-1RA therapy.
Objective. To systematically evaluate the clinical determinants of GLP-1RA-associated lean mass loss, define high-risk patient phenotypes, and appraise the available evidence for pharmacological and non-pharmacological mitigation strategies.
Methods. A structured narrative review of randomised controlled trials, post-hoc body composition analyses, and mechanistic studies published from 2018 to 2024 was conducted, drawing on dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA) substudy data from the STEP, SURMOUNT, and SCALE trial programmes. Evidence pertaining to resistance exercise prescription, dietary protein augmentation (≥1.2 g·kg?¹·day?¹), and adjunctive anabolic agents — including investigational myostatin inhibitors and leucine-enriched essential amino acid supplementation — was critically appraised.
Results and synthesis. Pooled substudy data indicate a mean ASMM reduction of 1.8–3.4 kg over 68-week GLP-1RA treatment periods, with losses amplified in patients aged ≥65 years, those with baseline ASMM index below sex-specific thresholds (EWGSOP2 criteria), and individuals with treatment-emergent anorexia exceeding 30% caloric restriction. Resistance training performed ≥2 sessions per week attenuated lean mass loss by approximately 45–60% in available intervention substudies, while concurrent high-protein dietary support demonstrated additive benefit. Pharmacological co-intervention with investigational dual GIP/GLP-1 agonists incorporating growth hormone secretagogue activity is under early-phase evaluation, with mechanistic rationale supported by GLP-1R expression on satellite cells and evidence of agonist-mediated mTORC1 suppression in myocyte cultures.
Conclusions. GLP-1RA-associated lean mass loss represents a clinically underacknowledged sequela of pharmacologically induced negative energy balance, with meaningful implications for functional capacity, metabolic rate preservation, and long-term weight maintenance. We propose a tiered clinical risk stratification framework integrating baseline body composition assessment, age, physical activity status, and protein intake adequacy, alongside a structured monitoring and intervention algorithm to be evaluated prospectively in future trials. Regulatory bodies and clinical guideline developers should consider mandating lean mass endpoints as co-primary outcomes in obesity pharmacotherapy trials.
Keywords: GLP-1 receptor agonists; sarcopaenia; lean mass preservation; semaglutide; tirzepatide; body composition; resistance exercise; dietary protein; mTORC1; obesity pharmacotherapy; EWGSOP2
